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oped severe sequelae, such as bilateral hearing loss or an intelligence quotient of ^0. In contrast, these sequelae occurred in 167o of infants whose mothers had primary infection during pregnancy. These observations suggest that immunity to HCMV before pregnancy will prevent the majority of severe sequelae associated with congenital infection.
Annually, of 4 million live births in the United States, ~8000 infants will develop sequelae or die due to congenital HCMV infection [3] . This low incidence of symptomatic congenital HCMV infection in the general population means that efficacy trials of HCMV vaccines with congenital infection as an end point will require immunization of large numbers of women. As an approach to assessing the potential for vaccine efficacy with a smaller number of subjects, we sought to determine if either wild type virus or vaccine-induced immunity protects against secondary infections among women with a very high risk of acquiring HCMV. Young infants with day care center-acquired HCMV infections excrete virus for 6-41 months and transmit HCMV to their seronegative mothers at an annual rate of 30^-50^ [4] [5] [6] . We therefore asked if immunization with the Towne strain of HCMV?a live attenuated vaccine that is effective in preventing severe HCMV-associated disease in renal transplant recipients?or immunity from a naturally acquired infection would reduce the rate at which mothers acquire HCMV infection from their children [7, 8] .
Materials and Methods
Subjects. Mothers of children ^ years old (each mother having at least 1 child shedding HCMV) were recruited between 1988 and 1993 from day care centers after screening the children for HCMV shedding. Seronegative mothers were enrolled at two sites, Richmond and Philadelphia, and were randomized and blinded to receive either a placebo or vaccine. Randomiza- Among 42 subjects who were seropositive at entry as a result of naturally acquired HCMV infection, 3 showed evidence of having acquired infection from their respective children. One woman, who knew her serologic status and never shed HCMV, had constant EIA titers (1:20,480) over the first 6 months of the study. In the ninth month, her EIA titer increased to 1:81,920. A second woman, whose status was blinded at entry, shed an HCMV isolate with a DNA pattern identical to that of her child 4 months after entry. Her EIA titer remained at 1:819,200 over the first 9 months of the study and gradually declined over the next 7 months. A third seropositive subject, also blinded, had a rise in EIA titer from 1:20,480 to 1:163,840 between the second and fourth month after entry and shed a small amount of HCMV ^10 pfu/mL) in a single urine specimen. The DNA pattern of that isolate was the same as the DNA pattern of the isolate shed by her child (figure 1).
After entry, 2 of 42 seropositive women shed HCMV with a DNA pattern different from that of the isolate shed by their children (figure 1). In the first, the isolate that differed was shed 6 months after entry. Her EIA titers were stable over a 2-year observation period. The second subject had HCMV infection at entry with an isolate unrelated by DNA pattern to that shed by her child. Her EIA titer at entry was 1:20,480 and increased to 1:81,920 by 2 months after entry, at which All subjects were prospectively monitored until either their child ceased shedding HCMV in ^2 consecutive samples of urine and saliva or until a subject showed evidence of an acquired HCMV infection. Evidence of an acquired HCMV infection was defined either as primary infection (seroconversion) with or without viral shedding or, when the woman was seropositive, as secondary infection: a 4-fold rise in HCMV antibody titers as determined by EIA without viral shedding or maternal shedding of a virus strain with the same restriction endonuclease DNA digestion pattern as the strain shed by her child. For 80 subjects, the average duration of monitoring was 18 months (range, 4-44). After entry, monitoring consisted of testing samples of urine and saliva from each subject and her child for the presence of virus at entry, every 2 weeks for 8 weeks, and monthly thereafter. Samples of serum and plasma were obtained from each mother at entry and 2, 4, and 6 months after entry and then every 3 months up to 1 year.
Vaccine. The Towne vaccine was prepared as described and administered subcutaneously in the deltoid region at ~500 pfu/ subject [9, 10] .
Laboratory methods. Urine and saliva samples were cultured before and after concentration in duplicate on MRC-5 fibroblasts as described [11] . White blood cells were prepared from each plasma sample and cultured for HCMV. Isolates were passed two to four times in MRC-5 fibroblasts and incubated for 48 h with [32P]orthophosphate. HCMV DNAs were extracted by a modified Hirt procedure [11] . All isolates were endonucleasedigested with EcoRl and BamHl. Restriction fragments of wild type isolates and of Towne strain of HCMV were separated by electrophoresis through 0.8^ agarose as described [11] . Isolates were considered different if they differed by two or more restriction fragments after EcoRl or BamHl digestion. Serologic assays. IgG to HCMV was measured by EIA as described [12, 13] . A titer was defined as the highest dilution of serum that produced an OD of ^0.1. Seroconversions and 4-fold changes in titer were confirmed by testing paired sera simultaneously in duplicate. IgM to HCMV was measured using a commercial EIA (Abbott, Abbott Park, IL). Neutralizing antibodies were determined by standard plaque reduction assay without complement [14] . A titer was defined as the highest dilution of serum that produced 50^ inhibition.
Lymphocyte proliferation responses (LPR). HCMV-specific LPR were determined as described [ 15] (table  4) . These titers were 10-to 20-fold higher than the vaccineinduced titers (table 4) . After a wild type infection, subjects who had previously received vaccine developed geometric mean EIA antibody titers 3-fold higher (P < .02) than those of subjects who received placebo and then acquired a wild type infection, suggesting that the latter had an amnestic response induced by the secondary infection (table 4).
Discussion
The major finding of this study is the relative protection afforded by a primary infection due to a wild type virus and the association of this protection with high levels of neutralizing antibodies to HCMV. Only 3 of 42 women with naturally acquired HCMV infection and high levels of antibody to HCMV showed possible evidence of having acquired their infection from their children. In contrast, nearly half of the women with vaccine-induced immunity and low levels of antibody to HCMV developed evidence of infection acquired from their children. Because the infection rate in the placebo recipients was similar to that of vaccinees, these observations suggest that high antibody levels derived from a wild type infection are associated with protection.
However, although we tried to avoid enrolling seropositive women whose primary infection was recently acquired from their child, in no case could we determine precisely when seropositive women first became infected or the source of infection. If reinfection rates are strain related, this may be important. Different strains of HCMV induce variable titers of both EIA and neutralizing antibodies in both humans and animals [13, 17, 18] . Presumably, the highest titers and hence the highest level of protection against a secondary infection will occur against the strain that caused the primary infection. However, it is unlikely either that a substantial portion of the women seropositive at entry had a primary infection acquired from their children or that a substantial portion of the children acquired HCMV congenitally from their mothers. In Richmond, 40*^ of women of childbearing age are seropositive, a rate similar to that we observed among mothers with children in day care who were shedding HCMV, and ^'3d of seropositive mothers give birth to infants with asymptomatic congenital HCMV infection [19] .
In the current study, a 4-fold elevation in EIA titer was the best indication of a secondary infection. All vaccinees had detectable levels of both neutralizing and EIA antibodies to HCMV before acquiring a wild type infection from their children. Each vaccinee who shed a wild type isolate also had a concomitant 4-fold rise in antibody, and no vaccinee shed HCMV without a serologic response. Among the recipients of placebo, the rate of seroconversion and shedding was similar to that observed in a previous study: about half of the women with infected children seroconverted, and of these, half had HCMV recovered from urine or saliva [4] .
Even though for purposes of data analysis in this study we considered 3 seropositive women to have had evidence of HCMV acquisition from their children, only 1 seropositive subject demonstrated entirely convincing evidence of a secondary infection acquired from her child: at 4 months after entry she both had a serologic response and shed an HCMV isolate with the DNA pattern of the isolate shed by her child. One of the other 2 women considered infected shed the same isolate as her child but did not have a serologic response. Thus, she may have had reactivation of an infection acquired before entry. The other woman had a serologic response to HCMV but no virus isolated. Thus, the source of her secondary infection could not be determined.
Two seropositive women were infected with isolates unrelated to their child's isolate. One of these may have been undergoing a primary infection at entry with an isolate that differed from that of her child, and the other was IgM-negative and had stable EIA titers. Over 2 years, neither developed evidence of having acquired CMV from her child.
The frequency of secondary infection in previously in-
